Page last updated: 2024-11-03

pyrimethamine and Stillbirth

pyrimethamine has been researched along with Stillbirth in 8 studies

Maloprim: contains above 2 cpds

Stillbirth: The event that a FETUS is born dead or stillborn.

Research Excerpts

ExcerptRelevanceReference
"Adequate prevention regimen with monthly sulfadoxine-pyrimethamine given to all pregnant women has been proved to reduce the risk of LBW in malaria endemic areas."9.69Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial. ( Derra, K; Donnen, P; Dramaix, M; Kaboré, B; Lingani, M; Robert, A; Rouamba, T; Samadoulougou, S; Sanou, M; Somé, G; Sorgho, H; Tahita, MC; Tinto, H; Valéa, I; Zango, SH, 2023)
"In the context of the increasing resistance to sulfadoxine-pyrimethamine (SP), we evaluated the efficacy of mefloquine (MQ) for intermittent preventive treatment during pregnancy (IPTp)."9.14Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. ( Ayemonna, P; Bottero, J; Briand, V; Cordel, H; Cot, M; Fayomi, B; Fievet, N; Guerra, J; Kossou, H; Masse, V; Massougbodji, A; Noël, H, 2009)
"Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity."8.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"Adequate prevention regimen with monthly sulfadoxine-pyrimethamine given to all pregnant women has been proved to reduce the risk of LBW in malaria endemic areas."5.69Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial. ( Derra, K; Donnen, P; Dramaix, M; Kaboré, B; Lingani, M; Robert, A; Rouamba, T; Samadoulougou, S; Sanou, M; Somé, G; Sorgho, H; Tahita, MC; Tinto, H; Valéa, I; Zango, SH, 2023)
"Emerging malaria parasite sulfadoxine-pyrimethamine (SP) resistance has prompted assessment of alternatives for intermittent preventive treatment in pregnancy (IPTp)."5.30A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women. ( Benjamin, JM; Davis, TME; Kasian, B; Kong, C; Laman, M; Moore, BR; Mueller, I; Ome-Kaius, M; Robinson, LJ; Rogerson, S; Tobe, R; Yadi, G, 2019)
"In the context of the increasing resistance to sulfadoxine-pyrimethamine (SP), we evaluated the efficacy of mefloquine (MQ) for intermittent preventive treatment during pregnancy (IPTp)."5.14Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. ( Ayemonna, P; Bottero, J; Briand, V; Cordel, H; Cot, M; Fayomi, B; Fievet, N; Guerra, J; Kossou, H; Masse, V; Massougbodji, A; Noël, H, 2009)
"Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity."4.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"Intermittent preventive treatment (IPTp) for pregnant women with sulfadoxine-pyrimethamine (SP) is widely implemented for the prevention of malaria in pregnancy and adverse birth outcomes."4.31Impact of Intermittent Presumptive Treatment for Malaria in Pregnancy on Hospital Birth Outcomes on the Kenyan Coast. ( Amadi, D; Bejon, P; Berkley, JA; Kamau, A; Musau, M; Mwakio, S; Nyaguara, A; Seale, AC; Snow, RW, 2023)
"Effective intermittent preventive treatment in pregnancy (IPTp) diminishes placental malaria (PM) and its subsequent malaria-associated morbidity."2.50Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. ( Abellana, R; Cot, M; Moya-Alvarez, V, 2014)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's4 (50.00)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Kamau, A1
Musau, M1
Mwakio, S1
Amadi, D1
Nyaguara, A1
Bejon, P1
Seale, AC1
Berkley, JA1
Snow, RW1
Lingani, M1
Zango, SH1
Valéa, I1
Samadoulougou, S1
Somé, G1
Sanou, M1
Kaboré, B1
Rouamba, T1
Sorgho, H1
Tahita, MC1
Derra, K1
Dramaix, M1
Tinto, H1
Donnen, P1
Robert, A1
Moore, BR1
Benjamin, JM1
Tobe, R1
Ome-Kaius, M1
Yadi, G1
Kasian, B1
Kong, C1
Robinson, LJ1
Laman, M1
Mueller, I1
Rogerson, S1
Davis, TME1
Ategeka, J1
Kakuru, A1
Kajubi, R1
Wasswa, R1
Ochokoru, H1
Arinaitwe, E1
Yeka, A1
Jagannathan, P1
Kamya, MR1
Muehlenbachs, A1
Chico, RM1
Dorsey, G1
González, R1
Pons-Duran, C1
Piqueras, M1
Aponte, JJ1
Ter Kuile, FO1
Menéndez, C1
Moya-Alvarez, V1
Abellana, R1
Cot, M3
Briand, V2
Escolano, S1
Journot, V1
Massougbodji, A2
Tubert-Bitter, P1
Bottero, J1
Noël, H1
Masse, V1
Cordel, H1
Guerra, J1
Kossou, H1
Fayomi, B1
Ayemonna, P1
Fievet, N1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants[NCT02793622]Phase 3782 participants (Actual)Interventional2016-09-30Completed
Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine[NCT00274235]Phase 31,600 participants (Anticipated)Interventional2005-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Incidence of Complicated Malaria in Infants

Complicated malaria defined as an episode of malaria with danger signs (any of the following: less than 3 convulsions over 24 h, inability to sit or stand, vomiting everything, unable to breastfeed or drink) or the meeting standardized criteria for severe malaria. (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy44
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy24

Incidence of Hospital Admissions in Infants

Admission to the pediatric ward for any cause (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy19
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy8

Incidence of Malaria in Infants

episodes per person year (NCT02793622)
Timeframe: Time at risk will begin at birth and end when study participants reaches 12 months of age or early study termination

Interventionepisodes per person year (Number)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy1.98
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy1.71

Infant Mortality Rate

Any deaths occurring after birth (NCT02793622)
Timeframe: Birth up to 12 months of age

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy9
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy7

Mean Gestational Age in Weeks at Birth

Gestational age in weeks determined by ultrasound dating (gold standard) and by the metabolic profiling outcome from biological specimens including placental tissue and placental blood. (NCT02793622)
Timeframe: At the time of delivery

Interventionweeks (Mean)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy39.4
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy39.6

Number of Participants Who Deliver With a Composite Adverse Birth Outcome

Composite adverse birth outcome defined as any one of the following: 1) Low birth weight (< 2500 gm); 2) Preterm delivery (< 37 weeks gestational age); 3) Small for gestational age (< 10th percentile relative to an external growth reference) (NCT02793622)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy60
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy54

Number of Participants With Adverse Events

All grade 3 and 4 adverse events (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy54
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy43

Prevalence of Anemia in Infants

"Defined as the proportion with hemoglobin < 10 g/dL measure routinely at 12, 28, and 52 weeks of age. Number of cases per person year (PPY).~This is a prevalence measure but are repeated measures during infancy. In other words we measured this outcome up to 3 times for each participant during infancy (at 12, 28 and 52 weeks of age)." (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination

Interventionroutine hemoglobin measurement (Count of Units)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy222
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy216

Prevalence of Anemia in Pregnant Women

hemoglobin < 11 g/dL (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy28
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy8

Prevalence of Asymptomatic Parasitemia in Infants

Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination

Interventionblood smears (Count of Units)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy344
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy357

Prevalence of Asymptomatic Parasitemia in Pregnant Women

Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery

Interventionblood smears (Count of Units)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy519
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy9

Prevalence of Maternal Malaria

Maternal blood positive for malaria parasites by microscopy. (NCT02793622)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy28
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy1

Prevalence of Placental Malaria by Histology

Any evidence of placental infection (parasites or pigment). Number of participants with placental tissue positive for malaria parasites or pigment. (NCT02793622)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy197
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy94

Prevalence of Placental Parasitemia

Proportion of placental blood samples positive for parasites by Loop-mediated isothermal amplification (LAMP) or microscopy (NCT02793622)
Timeframe: Delivery

,
InterventionParticipants (Count of Participants)
LAMPMicroscopy
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy71
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy7129

Reviews

2 reviews available for pyrimethamine and Stillbirth

ArticleYear
Mefloquine for preventing malaria in pregnant women.
    The Cochrane database of systematic reviews, 2018, 11-14, Volume: 11

    Topics: Anemia; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; HIV Seronegativity; Hum

2018
Pregnancy-associated malaria and malaria in infants: an old problem with present consequences.
    Malaria journal, 2014, Jul-11, Volume: 13

    Topics: Adult; Africa South of the Sahara; Antimalarials; Comorbidity; Complement Activation; Developmental

2014

Trials

4 trials available for pyrimethamine and Stillbirth

ArticleYear
Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial.
    Malaria journal, 2023, Mar-17, Volume: 22, Issue:1

    Topics: Abortion, Spontaneous; Antimalarials; Azithromycin; Birth Weight; Burkina Faso; Drug Combinations; F

2023
A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10

    Topics: Adult; Antimalarials; Asymptomatic Diseases; Azithromycin; Chemoprevention; Drug Combinations; Eryth

2019
Mefloquine Versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment in Pregnancy: A Joint Analysis on Efficacy and Tolerability.
    The American journal of tropical medicine and hygiene, 2015, Volume: 93, Issue:2

    Topics: Anemia; Antimalarials; Benin; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Malaria;

2015
Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine.
    The Journal of infectious diseases, 2009, Sep-15, Volume: 200, Issue:6

    Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Antimalarials; Drug Combinations; Female;

2009

Other Studies

2 other studies available for pyrimethamine and Stillbirth

ArticleYear
Impact of Intermittent Presumptive Treatment for Malaria in Pregnancy on Hospital Birth Outcomes on the Kenyan Coast.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Antimalarials; Drug Combinations; Female; Humans; Kenya; Malaria; Pregnancy; Pregnancy Complications

2023
Relationships Between Measures of Malaria at Delivery and Adverse Birth Outcomes in a High-Transmission Area of Uganda.
    The Journal of infectious diseases, 2020, 08-04, Volume: 222, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Infan

2020